Načítá se...
Secukinumab for ankylosing spondylitis and psoriatic arthritis
The treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) positively changed since the introduction of anti-TNFα drugs. These treatments were shown to reduce the symptoms and signs of the diseases and improve the quality of life. However, a variable percentage of patients do not res...
Uloženo v:
| Vydáno v: | Ther Clin Risk Manag |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5085310/ https://ncbi.nlm.nih.gov/pubmed/27799780 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S100091 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|